ID Biomedical announces rescheduling of court hearing to approve acquisition by GlaxoSmithKline
2005年11月19日 - 7:06AM
PRニュース・ワイアー (英語)
VANCOUVER, Nov. 18 /PRNewswire-FirstCall/ -- ID Biomedical
Corporation (TSX: IDB; NASDAQ: IDBE) ("ID Biomedical") announced
today that its application to the British Columbia Supreme Court to
approve the proposed acquisition of ID Biomedical by
GlaxoSmithKline plc. and GlaxoSmithKline Inc. has been rescheduled
from today to Friday, December 2, 2005. Completion of the proposed
transaction remains subject to a number of conditions, including
receipt of certain regulatory approvals and approval of the British
Columbia Supreme Court. ID Biomedical continues to expect the
transaction to be completed by late 2005 or early 2006. ID
Biomedical will provide further updates on the expected timing of
the proposed transaction in the near future. About ID Biomedical ID
Biomedical is an integrated biotechnology company dedicated to the
development of innovative vaccine products. It operates in
research, development, manufacturing, sales and marketing from its
facilities in Canada and in the United States. ID Biomedical is
dedicated to becoming a premier vaccine company with significant
marketed products worldwide and an extensive pipeline in both
clinical and preclinical development. ID Biomedical has a leading
position in the Canadian influenza market. It received a ten year
mandate from the Government of Canada in 2001 to assure a state of
readiness in the case of an influenza pandemic and provide
influenza vaccine for all Canadians in such an event. It also
currently supplies approximately 75% of the Canadian government's
influenza vaccine purchases. The information in this news release
contains so-called "forward-looking" statements. These include
statements regarding ID Biomedical's expectations and plans
relating to the interaction of the vaccine business acquired from
Shire, statements about ID Biomedical's expectations, beliefs,
intentions or strategies for the future, which may be indicated by
words or phrases such as "anticipate", "expect", "intend", "plan",
"will", "we believe", "ID Biomedical believes", "management
believes", and similar language. All forward-looking statements are
based on ID Biomedical's current expectations and are subject to
risks and uncertainties and to assumptions made. Important factors
that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements include:
(i) the company's ability to successfully complete the proposed
GlaxoSmithKline transaction; (ii) the company's ability to
successfully complete preclinical and clinical development of its
products; (iii) the company's ability to manufacture its products;
(iv) the seasonality of the flu-vaccine business and related
fluctuations in the company's revenues from quarter to quarter; (v)
decisions, and the timing of decisions, made by the health
regulatory agencies regarding approval of its products for human
testing; (vi) the company's ability to enter into distribution
agreements for its products, and to complete and maintain corporate
alliances relating to the development and commercialization of its
technology and products; (vii) market acceptance of its
technologies and products; and (viii) the competitive environment
and impact of technological change and other risks detailed in the
company's filings with the Securities and Exchange Commission. ID
Biomedical bases its forward- looking statements on information
currently available to it, and assumes no obligation to update
them. For further information, please contact: Investor
Relations/Media Dean Linden Michele Roy (604) 431-9314 (450)
978-6313 DATASOURCE: ID Biomedical Corporation CONTACT: Investor
Relations/Media, Dean Linden, (604) 431-9314, ; Michele Roy, (450)
978-6313, ; To request a free copy of this organization's annual
report, please go to http://www.newswire.ca/ and click on Tools for
Investors.
Copyright